Unknown

Dataset Information

0

An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease.


ABSTRACT: Alzheimer's disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD. MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients.

SUBMITTER: Shah RC 

PROVIDER: S-EPMC4153084 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease.

Shah Raj C RC   Matthews Dawn C DC   Andrews Randolph D RD   Capuano Ana W AW   Fleischman Debra A DA   VanderLugt James T JT   Colca Jerry R JR  

Current Alzheimer research 20140101 6


Alzheimer's disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD. MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pr  ...[more]

Similar Datasets

| S-EPMC3604641 | biostudies-literature
| S-EPMC7981362 | biostudies-literature
| S-EPMC6180432 | biostudies-literature
2016-02-17 | E-GEOD-53697 | biostudies-arrayexpress
| S-EPMC4021072 | biostudies-literature
2016-02-17 | GSE53697 | GEO
| S-EPMC5975050 | biostudies-literature
| S-EPMC3695013 | biostudies-literature
| S-EPMC5393926 | biostudies-literature
| S-EPMC4253975 | biostudies-literature